ahlam1399
08-10-2016, 06:32 PM
Lilly breast cancer drug stumbles, but trial continues
(Reuters) - U.S. drugmaker Eli Lilly and Co on Wednesday said it would continue a late-stage trial of its experimental breast cancer drug in combination with a widely used treatment even though an independent panel determined the combination therapy failed to meet its interim effectiveness goal.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=gr9UYa2AWOo:SY6SoJOuJFE:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=gr9UYa2AWOo:SY6SoJOuJFE:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=gr9UYa2AWOo:SY6SoJOuJFE:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=gr9UYa2AWOo:SY6SoJOuJFE:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=gr9UYa2AWOo:SY6SoJOuJFE:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/gr9UYa2AWOo
(Reuters) - U.S. drugmaker Eli Lilly and Co on Wednesday said it would continue a late-stage trial of its experimental breast cancer drug in combination with a widely used treatment even though an independent panel determined the combination therapy failed to meet its interim effectiveness goal.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=gr9UYa2AWOo:SY6SoJOuJFE:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=gr9UYa2AWOo:SY6SoJOuJFE:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=gr9UYa2AWOo:SY6SoJOuJFE:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=gr9UYa2AWOo:SY6SoJOuJFE:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=gr9UYa2AWOo:SY6SoJOuJFE:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/gr9UYa2AWOo